230 related articles for article (PubMed ID: 19536896)
41. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
[TBL] [Abstract][Full Text] [Related]
42. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients.
Brambilla L; Bellinvia M; Tourlaki A; Scoppio B; Gaiani F; Boneschi V
Br J Dermatol; 2010 Apr; 162(4):854-9. PubMed ID: 19995366
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.
Bedikian AY; Silverman JA; Papadopoulos NE; Kim KB; Hagey AE; Vardeleon A; Hwu WJ; Homsi J; Davies M; Hwu P
J Clin Pharmacol; 2011 Aug; 51(8):1205-12. PubMed ID: 20978276
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
45. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Lazar AD; Shpilberg O; Shaklai M; Bairey O
Isr Med Assoc J; 2009 Jan; 11(1):16-22. PubMed ID: 19344007
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy.
Osterborg A; Steegmann JL; Hellmann A; Couban S; Mayer J; Eid JE
Br J Haematol; 2007 Mar; 136(5):736-44. PubMed ID: 17313376
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients.
Bedikian AY; Vardeleon A; Smith T; Campbell S; Namdari R
J Clin Pharmacol; 2006 Jul; 46(7):727-37. PubMed ID: 16809798
[TBL] [Abstract][Full Text] [Related]
48. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
Oki Y; McLaughlin P; Fayad LE; Pro B; Mansfield PF; Clayman GL; Medeiros LJ; Kwak LW; Srivastava PK; Younes A
Cancer; 2007 Jan; 109(1):77-83. PubMed ID: 17133412
[TBL] [Abstract][Full Text] [Related]
49. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases.
Brambilla L; Romanelli A; Bellinvia M; Ferrucci S; Vinci M; Boneschi V; Miedico A; Tedeschi L
Br J Dermatol; 2008 Jun; 158(6):1339-44. PubMed ID: 18363766
[TBL] [Abstract][Full Text] [Related]
50. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
51. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
52. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
53. Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia.
Harrison TS; Lyseng-Williamson KA
BioDrugs; 2013 Feb; 27(1):69-74. PubMed ID: 23329395
[TBL] [Abstract][Full Text] [Related]
54. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Nishimori H; Fujii N; Maeda Y; Matsuoka K; Takenaka K; Shinagawa K; Ikeda K; Matsuo K; Harada M; Tanimoto M
Anticancer Res; 2009 May; 29(5):1749-54. PubMed ID: 19443398
[TBL] [Abstract][Full Text] [Related]
56. [Clinical effect of idarubicin on malignant lymphoma].
Urabe A; Ohno R; Kuraishi Y; Masaoka T; Ohashi Y; Ogawa M
Gan To Kagaku Ryoho; 1999 Aug; 26(9):1275-82. PubMed ID: 10478180
[TBL] [Abstract][Full Text] [Related]
57. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Thomas DA; Kantarjian HM; Stock W; Heffner LT; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Pierce S; Lu B; Deitcher SR; O'Brien S
Cancer; 2009 Dec; 115(23):5490-8. PubMed ID: 19708032
[TBL] [Abstract][Full Text] [Related]
58. Thalidomide for patients with recurrent lymphoma.
Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F
Cancer; 2004 Mar; 100(6):1186-9. PubMed ID: 15022285
[TBL] [Abstract][Full Text] [Related]
59. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Pettengell R; Coiffier B; Egorov A; Singer J; Sivcheva L
Clin Drug Investig; 2018 Jun; 38(6):527-533. PubMed ID: 29564722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]